Read More Pharma Industry News AstraZeneca’s Lynparza shows promising results in phase 3 ovarian cancer trial AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib),… bypharmanewsdailyMarch 18, 2017
